Cargando…

Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics

BACKGROUND: Pharmacokinetic and pharmacodynamic (PK/PD) indices are increasingly being used in the microbiological field to assess the efficacy of a dosing regimen. In contrast to methods using MIC, PK/PD-based methods reflect in vivo conditions and are more predictive of efficacy. Unfortunately, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Goue Denis Gohore, Li, Jun, Nekka, Fahima
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709609/
https://www.ncbi.nlm.nih.gov/pubmed/19558679
http://dx.doi.org/10.1186/1742-4682-6-10
_version_ 1782169310572052480
author Bi, Goue Denis Gohore
Li, Jun
Nekka, Fahima
author_facet Bi, Goue Denis Gohore
Li, Jun
Nekka, Fahima
author_sort Bi, Goue Denis Gohore
collection PubMed
description BACKGROUND: Pharmacokinetic and pharmacodynamic (PK/PD) indices are increasingly being used in the microbiological field to assess the efficacy of a dosing regimen. In contrast to methods using MIC, PK/PD-based methods reflect in vivo conditions and are more predictive of efficacy. Unfortunately, they entail the use of one PK-derived value such as AUC or Cmax and may thus lead to biased efficiency information when the variability is large. The aim of the present work was to evaluate the efficacy of a treatment by adjusting classical breakpoint estimation methods to the situation of variable PK profiles. METHODS AND RESULTS: We propose a logical generalisation of the usual AUC methods by introducing the concept of "efficiency" for a PK profile, which involves the efficacy function as a weight. We formulated these methods for both classes of concentration- and time-dependent antibiotics. Using drug models and in silico approaches, we provide a theoretical basis for characterizing the efficiency of a PK profile under in vivo conditions. We also used the particular case of variable drug intake to assess the effect of the variable PK profiles generated and to analyse the implications for breakpoint estimation. CONCLUSION: Compared to traditional methods, our weighted AUC approach gives a more powerful PK/PD link and reveals, through examples, interesting issues about the uniqueness of therapeutic outcome indices and antibiotic resistance problems.
format Text
id pubmed-2709609
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27096092009-07-14 Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics Bi, Goue Denis Gohore Li, Jun Nekka, Fahima Theor Biol Med Model Research BACKGROUND: Pharmacokinetic and pharmacodynamic (PK/PD) indices are increasingly being used in the microbiological field to assess the efficacy of a dosing regimen. In contrast to methods using MIC, PK/PD-based methods reflect in vivo conditions and are more predictive of efficacy. Unfortunately, they entail the use of one PK-derived value such as AUC or Cmax and may thus lead to biased efficiency information when the variability is large. The aim of the present work was to evaluate the efficacy of a treatment by adjusting classical breakpoint estimation methods to the situation of variable PK profiles. METHODS AND RESULTS: We propose a logical generalisation of the usual AUC methods by introducing the concept of "efficiency" for a PK profile, which involves the efficacy function as a weight. We formulated these methods for both classes of concentration- and time-dependent antibiotics. Using drug models and in silico approaches, we provide a theoretical basis for characterizing the efficiency of a PK profile under in vivo conditions. We also used the particular case of variable drug intake to assess the effect of the variable PK profiles generated and to analyse the implications for breakpoint estimation. CONCLUSION: Compared to traditional methods, our weighted AUC approach gives a more powerful PK/PD link and reveals, through examples, interesting issues about the uniqueness of therapeutic outcome indices and antibiotic resistance problems. BioMed Central 2009-06-26 /pmc/articles/PMC2709609/ /pubmed/19558679 http://dx.doi.org/10.1186/1742-4682-6-10 Text en Copyright © 2009 Bi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bi, Goue Denis Gohore
Li, Jun
Nekka, Fahima
Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
title Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
title_full Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
title_fullStr Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
title_full_unstemmed Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
title_short Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
title_sort antimicrobial breakpoint estimation accounting for variability in pharmacokinetics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709609/
https://www.ncbi.nlm.nih.gov/pubmed/19558679
http://dx.doi.org/10.1186/1742-4682-6-10
work_keys_str_mv AT bigouedenisgohore antimicrobialbreakpointestimationaccountingforvariabilityinpharmacokinetics
AT lijun antimicrobialbreakpointestimationaccountingforvariabilityinpharmacokinetics
AT nekkafahima antimicrobialbreakpointestimationaccountingforvariabilityinpharmacokinetics